A hipericina aumenta a eficácia do laser de alta potência? Um estudo preliminar e experimental em ratos
Palavras-chave:
Hypericum, Lasers de estado sólido, Hiperplasia prostática, Fotoquimioterapia, EndoscopiaResumo
CONTEXTO E OBJETIVO: Lasers são amplamente utilizados no tratamento de hiperplasia benigna de próstata sintomática. Na prática atual, lasers de fosfato de titanilo de potássio (KTP) são os tipos mais comuns usados dos sistemas. O objetivo foi avaliar o efeito rápido do sistema laser de alta potência após a aplicação de hipericina. TIPO DE ESTUDO E LOCAL: Estudo experimental animal, realizado no Departamento de Urologia, Academia de Medicina Militar de Gülhane, Ancara, Turquia, em 2012. MÉTODOS: 16 ratos foram divididos aleatoriamente em 4 grupos: 120W KTP laser + hipericina; 120W KTP laser somente; 80W KTP laser + hipericina; 80W KTP laser somente. Hipericina foi dada intraperitonealmente duas horas antes da aplicação do laser. As incisões a laser foram feitas através do músculo quadríceps dos ratos. A profundidade e a largura das incisões a laser foram avaliadas histologicamente e registradas. RESULTADOS: Para padronizar o efeito do laser foi utilizada a razão entre profundidade e largura. Estes novos valores nos mostraram a profundidade da aplicação do laser de largura por unidade. Os novos valores adquiridos foram avaliados estatisticamente. Os valores da média de profundidade/largura foram 231,6, 173,6, 214,1 e 178,9 nos grupos 1, 2, 3 e 4, respectivamente. O resultado mais notável foi atingir altos graus de penetração tecidual nos grupos com hipericina (P < 0,05). CONCLUSÕES: Os resultados promissores do nosso estudo preliminar mostraram que hipericina pode melhorar os efeitos das aplicações do laser KTP.
Downloads
Referências
Malek RS, Nahen K. Photoselective vaporization of the prostate: KTP laser therapy of obstructive benign prostatic hyperplasia. AUA Update Ser. 2004;23:153-60.
Anson K. Could the latest generation potassium titanyl phosphate lasers be the ones to make transurethral resection of the prostate an operation of historical interest only? Curr Opin Urol. 2004;14(1):27-9.
Kasper S. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry. 1997;30 Suppl 2:89-93.
Vitiello B. Hypericum perforatum extracts as potential antidepressants. J Pharm Pharmacol. 1999;51(5):513-7.
Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889-905.
Thomas C, MacGill RS, Miller GC, Pardini RS. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase. Photochem Photobiol. 1992;55(1):47-53.
Diwu Z, Lown JW. Photosensitization with anticancer agents. 17. EPR studies of photodynamic action of hypericin: formation of semiquinone radical and activated oxygen species on illumination. Free Radic Biol Med. 1993;14(2):209-15.
Ebermann R, Alth G, Kreitner M, Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J Photochem Photobiol B. 1996;36(2):95-7.
VanderWerf QM, Saxton RE, Chang A, et al. Hypericin: a new laser phototargeting agent for human cancer cells. Laryngoscope. 1996;106(4):479-83.
Chung PS, Rhee CK, Kim KH, et al. Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma. Laryngoscope. 2000;110(8):1312-6.
Kamuhabwa AA, Roskams T, D‘Hallewin MA, et al. Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumors using intravesically administered hypericin. Int J Cancer. 2003;107(3):460-7.
Liu CD, Kwan D, Saxton RE, McFadden DW. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res. 2000;93(1):137-43.
Blank M, Kostenich G, Lavie G, et al. Wavelength-dependent properties of photodynamic therapy using hypericin in vitro and in an animal model. Photochem Photobiol. 2002;76(3):335-40.
Solár P, Cavarga I, Hofmanová J, et al. Effect of acetazolamide on hypericin photocytotoxicity. Planta Med. 2002;68(7):658-60.
Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A. 1988;85(14):5230-4.
Okpanyi SN, Lidzba H, Scholl BC, Miltenburger HG. Genotoxizität eines standardisierten Hypericum-Extraktes. [Genotoxicity of a standardized Hypericum extract]. Arzneimittelforschung. 1990;40(8):851-5.
Linde K, Ramirez G, Mulrow CD, et al. St John’s wort for depression-
-an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313(7052):253-8.
Koren H, Schenk GM, Jindra RH, et al. Hypericin in phototherapy. J Photochem Photobiol B. 1996;36(2):113-9.
Kubin A, Alth G, Jindra R, Jessner G, Ebermann R. Wavelength- dependent photoresponse of biological and aqueous model systems using the photodynamic plant pigment hypericin. J Photochem Photobiol B. 1996;36(2):103-8.
Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg. 1996;14(5):323-8.
Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg. 1996;14(5):329-34.
Vandenbogaerde AL, Geboes KR, Cuveele JF, et al. Antitumour activity of photosensitized hypericin on A431 cell xenografts. Anticancer Res. 1996;16(4A):1619-25.
Chen B, de Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000;150(1):111-7.
Chen B, Xu Y, Roskams T, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer. 2001;93(2):275-82.
Vantieghem A, Assefa Z, Vandenabeele P, et al. Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett. 1998;440(1-2):19-24.
Bachmann A, Ruszat R. The KTP-(greenlight) laser--principles and experiences. Minim Invasive Ther Allied Technol. 2007;16(1):5-10.
Assefa Z, Vantieghem A, Declercq W, et al. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem. 1999;274(13):8788-96.
Hamilton HB, Hinton DR, Law RE, et al. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg. 1996;85(2):329-34.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
